Biocryst Pharmaceuticals (BCRX) Revenue (2010 - 2026)

Biocryst Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $156.4 million for Q1 2026.

• Quarterly Revenue rose 7.48% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479.9 million (down 4.69% YoY) and the FY2025 annual result came in at $874.8 million, up 94.1% from the prior year.
• Revenue was $156.4 million for Q1 2026 at Biocryst Pharmaceuticals, up from $708000.0 in the prior quarter.
• Across five years, Revenue topped out at $163.4 million in Q2 2025 and bottomed at $708000.0 in Q4 2025.
• A 5-year average of $98.7 million and a median of $92.8 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 161.94% — and 2025, when it plunged 99.46%.
• Biocryst Pharmaceuticals' Revenue stood at $79.5 million in 2022, then rose by 17.42% to $93.4 million in 2023, then soared by 40.83% to $131.5 million in 2024, then plunged by 99.46% to $708000.0 in 2025, then jumped by 21992.23% to $156.4 million in 2026.
• Business Quant data shows BCRX's Revenue at $156.4 million in Q1 2026, $708000.0 in Q4 2025, and $159.4 million in Q3 2025.